🇺🇸 BIAsp30 in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 6
Most-reported reactions
- Angina Pectoris — 1 report (16.67%)
- Angina Unstable — 1 report (16.67%)
- Chest Pain — 1 report (16.67%)
- Hypoglycaemia — 1 report (16.67%)
- Left Ventricular Hypertrophy — 1 report (16.67%)
- Nephrotic Syndrome — 1 report (16.67%)
Other Diabetes approved in United States
Frequently asked questions
Is BIAsp30 approved in United States?
BIAsp30 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for BIAsp30 in United States?
The First Hospital of Jilin University is the originator. The local marketing authorisation holder may differ — check the official source linked above.